| Stereochemistry | ACHIRAL |
| Molecular Formula | C8H6N2O |
| Molecular Weight | 146.146 |
| Optical Activity | NONE |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
O=C1N=CNC2=CC=CC=C12
InChI
InChIKey=QMNUDYFKZYBWQX-UHFFFAOYSA-N
InChI=1S/C8H6N2O/c11-8-6-3-1-2-4-7(6)9-5-10-8/h1-5H,(H,9,10,11)
4-Hydroxyquinazoline is been used to inhibit PARP (poly(ADP-ribose) synthetase) which catalyzes covalent attachment of the ADP-ribose moiety of NAD+ to various proteins. This compound specifically and potently inhibits PARP-1. 4-HQN demonstrates the ability to decrease activation of transcription factor NFκB and AP-1 in lipopolysaccharide-induced shock. Mechanistic studies indicate that 4-HQN activates PI3-kinase/Akt pathway in the liver, spleen, and lung and down-regulates two elements of the MAP kinase system. Additionally, this agent has been observed to decrease ischemia-reperfusion-induced increase of protein oxidation, single-strand DNA breaks, lipid peroxidation, and mitochondrial reactive oxygen species production in the reperfusion period.
Originator
Approval Year
Sample Use Guides
Rats were treated with 4-Hydroxyquinazoline at a sublethal dose level (2 mg/Kg)
Route of Administration:
Oral
H9c2(2-1) cardiomyoblasts were incubated without (negative control) and with 1 mM hydrogen peroxide for 3 h either untreated (positive control) or treated with 4-hydroxyquinazoline (in 5, 10, 50, 100 and 200 mM) or HO-3089 (in 0.02, 0.05, 0.1, 10 and 50 mM). At the end of the incubation period the survival of cells was determined by the MTT assay
SUBSTANCE RECORD
